Anteris Technologies Ltd (AVR)

AVR Chart

vs Index S&P/ASX 20 S&P/ASX 50 S&P/ASX 100 S&P/ASX 200 S&P/ASX 300 All Ordinaries Small Ordinaries All Technology Consumer Staples Energy Financials Health Care Industrials Info Technology Materials Real Estate Comm. Services Utilities

Advanced

Show News Mov Avgs 10-day 20-day 30-day 50-day 100-day 150-day 200-day Mov Avgs 9-day 21-day 30-day 200-day Simple Exponential Weighted vs Index S&P/ASX 20 S&P/ASX 50 S&P/ASX 100 S&P/ASX 200 S&P/ASX 300 All Ordinaries Small Ordinaries All Technology Consumer Staples Energy Financials Health Care Industrials Info Technology Materials Real Estate Comm. Services Utilities

Mov Avgs 10-day 20-day 30-day 50-day 100-day 150-day 200-day 9/21 Cross 10/30 Cross Golden Cross Vol RSI BB

Day 3m 1yr 5yr 10yr

AVR's Principal Activity is the sale, distribution, maintenance and implementation of infusion solutions to major hospitals and health facilities in Australia and New Zealand; The manufacturing, sale and distribution of proprietary ADAPT regenerative tissue products globally; and Continued research and development of regenerative medicine and immunotherapies.

Announcements

Company Overview

Dividend History

Directors & Management

Name	Title	Since	Bio
Dr Yanheng Wu	Non-Executive Director	Dec 2018	Dr Yanheng Wu Non-Executive Director Dr Wu is the President and Vice chair of Constellation International (Group) Holdings Ltd. In 2016, he established Guangzhou Hearty-Care Biotechnology Ltd., a medical technology company that is now owned by Constellation International (Group) Holdings Ltd. He holds multiple biomedical patents.
Mr Stephen (Steve) Denaro	Company Secretary, Non-Executive Director	Oct 2018	Mr Stephen (Steve) Denaro Company Secretary, Non-Executive Director Mr Denaro has more than 30 years of senior level and Board level experience across publicly listed companies; serving as Chief Financial Officer, Company Secretary and Director. He has experience in managing compliance with finance and accounting regulatory requirements. He has managed investment acquisitions and subsequent funding (domestic and international). He also chairs the Risk Management Committee.
Dr Wenyi Gu	Non-Executive Director	Oct 2018	Dr Wenyi Gu Non-Executive Director Dr Gu works as Research Fellow for the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland (UQ), where he began his post-doctoral work in 2001. He was supported by the National Health and Medical Research Council (NHMRC) to work at Harvard Medical School, Harvard University as a visiting research fellow. Before he was into nano medicine (focusing on drug delivery and cancer therapy), he worked on RNAi-based gene therapy for several years at Translation Research Institute (TRI). His research has been published in respected industry journals such as Nature Communications, Ad. Materials, ACS Nano and PNAS USA. He is a Nominee Non-Executive Director for major shareholder, Star Bright Holding Ltd. He is also a member of Risk Management Committee.
Mr Mathew James Ratty	Executive Director, Chief Executive Officer, Managing Director	Dec 2017	Mr Mathew James Ratty Executive Director, Chief Executive Officer, Managing Director Mr Ratty is an experienced investor in Australian and US equity and debt markets. He has experience across capital raising advice, seed investment negotiation, corporate strategy and financial modelling. He is the co-founder of MC Management Group Pty Ltd. At MC Management Group Pty Ltd Mr Ratty holds the position of Head of Investment and is responsible for negotiating deal structures and asset pricing for companies in the healthcare, financial and technology space. Prior to this, Mr Ratty was a director and analyst at property development and equity company, Gladstone Bridge.
Mr Robert (Rob) E.T Towner	Non-Executive Director	Feb 2017	Mr Robert (Rob) E.T Towner Non-Executive Director Mr Towner has over 20 years of experience in the corporate advisory and finance sectors. He was appointed Managing Director & CEO of Triangle Energy (Global) Ltd in July 2014 and managed the Company's transition from operating Indonesian based assets to establishing a portfolio of Australian oil and gas projects, including the producing Cliff Head Oil Field and associated infrastructure in the Perth Basin, Western Australia. Rob has experience in the oil and gas sector and has been involved in a number of capital raisings for projects throughout Australia, Canada, Asia and the USA since the early 1990's. Rob represents Triangle's 32.68% interest on the board of State Gas Ltd as a non-executive Director.
Mr Wayne Paterson	Managing Director, Chief Executive Officer	Feb 2016	Mr Wayne Paterson Managing Director, Chief Executive Officer Mr Paterson has held senior positions in multi national pharmaceutical companies during the past 25 years. Throughout his career, he has been responsible for building and managing multi-billion dollar businesses throughout the world, including mergers, integrations, acquisitions and major restructures as President and CEO. From 2005 to 2013 he held senior positions at Merck Kgaa, most recently as President of Europe, Canada and Australia. Prior to this, he was President of Emerging Markets, President of Japan and Global Head of Cardiovascular Medicine. Between 1999 and 2005, he served at Roche Pharmaceuticals where he was most recently Head of Pharmaceuticals in Roche's South Korean operation. He also served as Head of Commercial Operations for Roche China based in Shanghai. He held as a director in Cepheid Inc from April 2015 to November 2016.
Mr John Seaberg	Non-Executive Director, Non-Executive Chairman	Oct 2014	Mr John Seaberg Non-Executive Director, Non-Executive Chairman Mr Seaberg served as Chairman of the Board of Synovis Inc, a Minneapolis based manufacturer of various medical devices and bio scaffold tissue products from 2008 until its sale to Baxter in 2012. From 2007 until 2014 he was Founder, Chairman and CEO of NeoChord Inc., a venture capital backed company commercializing technology developed at the Mayo Clinic for the repair of the mitral valve via minimally invasive techniques. From 1996 to 2006, he served at Guidant Corp (subsequently acquired by Boston Scientific Corp) where he served in various executive level positions including Director of Bradycardia Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Management. In 1991, he was co-founder of ACIST Medical and served as its first President and CEO. He is also a member of Member of the Risk Management Committee.
Mr Robert Norman Scott	Lead, Non-Executive Director	Mar 2013	Mr Robert Norman Scott Lead, Non-Executive Director Mr Scott has over 35 years' experience as a corporate advisor. Mr. Scott is a former senior partner of the international accounting firms of KPMG and Arthur Andersen. Mr. Scott is the Chair of the Risk and Disclosure Committee.
Mr Peter R Turvey	Non-Executive Director, Non-Executive Deputy Chairman	Mar 2012	Mr Peter R Turvey Non-Executive Director, Non-Executive Deputy Chairman Mr Turvey has had more than 30 years of experience in the biotech/pharmaceutical industry having been former Executive Vice President Licensing, Group General Counsel and Company Secretary of global biopharmaceutical company CSL, retiring in 2011. He was also part of the protection and licensing of CSL's intellectual property and for risk management within CSL, which included management of the internal audit function, reporting to the Audit & Risk Management Committee of the Board as well as being the Chairman of the Corporate Risk Management Committee. In his senior executive role at CSL, he was part of CSL's M&A and equity capital raising activities over a 15 year period, including during the time of the float of CSL as a publicly listed company. In addition to his expertise in corporate finance, audit and risk management, Mr Turvey has experience in commercialisation and pharmaceutical product development. Mr Turvey is currently Chairman of ImmVirX Pty Ltd, a NonExecutive Director of Cell Therapies Pty Ltd (a subsidiary of the Peter MacCallum Cancer Centre), and a director of Agriculture Victoria Services Pty Ltd and Phytogene Pty Ltd. He is Chairman of the Risk Committee.
Ms Catherine (Kate) Mary Costello	Non-Executive Director, Non-Executive Chairman	Aug 2005	Ms Catherine (Kate) Mary Costello Non-Executive Director, Non-Executive Chairman Ms Costello is a professional, Non-executive Director having sold her consultancy, Governance Matters, in 2017. Prior to establishing Governance Matters she worked in management at a commercial law firm and is an expert in strategy, governance and commercial law. Kate's board experience has spanned commercial, statutory and not-for-profit entities across diverse sectors: banking and finance; engineering; defence; biotech; entertainment; gaming; software; education; employment; housing and accommodation and professional services. She is a Director of Whittles Management Services Pty Ltd, a trustee of Adelaide Workers' Homes and a member of the Diocesan Finance Council of the Adelaide Archdiocese of the Catholic Church. She is an expert in corporate governance, board performance and strategy.
Lishan Zhang		N/A
Simon Buckingham		N/A
Christopher Catlow		N/A
William Rowley		N/A
Lee Rodne		N/A
Michael Bennett		N/A

Show All

Director Transactions

Date	Director	Type	Amount	Price	Value	Notes
10/12/20	Wayne Paterson	Expiry	1,000	$3.80	$3,800	Options expired
10/12/20	John Seaberg	Expiry	1,000	$3.80	$3,800	Options expired
20/03/20	Stephen (Steve) Denaro	Issued	25,000	$3.50	$87,500	Issue of options
20/03/20	Wayne Paterson	Issued	350,000	$3.50	$1,225,000	Issue of options
20/03/20	John Seaberg	Issued	60,000	$3.50	$210,000	Issue of options
20/03/20	Stephen (Steve) Denaro	Issued	25,000	$3.50	$87,500	Issue of options
20/03/20	Wayne Paterson	Issued	350,000	$3.50	$1,225,000	Issue of options
20/03/20	John Seaberg	Issued	60,000	$3.50	$210,000	Issue of options
18/12/18	Wayne Paterson	Issued	700,000	$0.061	$42,700	Rights issue
18/12/18	John Seaberg	Issued	700,000	$0.08	$56,000	Rights issue
18/12/18	Yanheng Wu	Issued	47,178,461	$0.08	$3,774,278	Rights issue
18/12/18	Lishan Zhang	Issued	62,897,248	$0.061	$3,836,732	Rights issue
18/12/18	Wayne Paterson	Issued	700,000	$0.08	$56,000	Rights issue
18/12/18	Yanheng Wu	Issued	47,178,461	$0.061	$2,877,886	Rights issue
18/12/18	Lishan Zhang	Issued	62,897,248	$0.08	$5,031,781	Rights issue
18/12/18	John Seaberg	Issued	700,000	$0.061	$42,700	Rights issue
28/06/18	Simon Buckingham	Issued	333,333	$0.30	$100,000	Placement
28/06/18	Wayne Paterson	Issued	166,667	$0.30	$50,000	Placement
28/06/18	John Seaberg	Issued	166,667	$0.30	$50,000	Placement
08/06/18	Catherine (Kate) Costello	Issued	418,817	$0.124	$51,869	Issue of options
08/06/18	Wayne Paterson	Issued	1,435,630	$0.124	$177,798	Issue of options

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Wayne Paterson	10/12/2020	916,667	N/A	403,248	N/A
John Seaberg	10/12/2020	885,703	N/A	67,000	N/A
Stephen (Steve) Denaro	20/03/2020	0	N/A	25,000	N/A
Wenyi Gu	N/A	N/A	N/A	N/A	N/A

Show All

Top 20 Shareholders About the Data

Name	Shares	Capital
Constellation Intl Holdings Limited	730,192	12.35%
HSBC Custody Nominees (Australia) Limited A/C 2	652,219	11.04%
Constellation Immunotherapy Limited	402,093	6.80%
National Nominees Limited <Db A/C>	373,228	6.31%
HSBC Custody Nominees (Australia) Limited Gsco Eca	290,293	4.91%
Star Bright Holding Limited	173,680	2.94%
Merrill Lynch (Australia) Nominees Pty Limited <Mlpro A/C>	169,733	2.87%
J P Morgan Nominees Australia Pty Limited	87,768	1.48%
Citicorp Nominees Pty Limited	84,369	1.43%
Mr Patrick Chew	73,670	1.25%
Dr Abdul Ahad Khan	36,895	0.62%
Mr Daniel Bernard Clough	33,584	0.57%
Through2 Investments Pty Ltd <Through2 Super Fund A/C>	33,000	0.56%
Mr Roger Anthony Pierce	32,673	0.55%
Bulldog Shale Pty Ltd <Bulldog Shale S Fund A/C>	30,000	0.51%
Carron Services Limited	28,572	0.48%
Mr Joseph John Doyle and Mrs Cheryl Anne Doyle	23,527	0.40%
Mr Athanasios Farmakis	23,000	0.39%
Zcsf Nominees Pty Ltd <Zoeller Superfund A/C>	20,505	0.35%
Mr Dale Anthony Reed	20,000	0.34%
Appwam Pty Ltd	20,000	0.34%
Mrs Janet Louise Bowtell and Mr Gary Owen Bowtell <Bowtell Super Fund A/C>	20,000	0.34%

Show All

Shareholder Distribution

Substantial Shareholders

Shareholders Buying

Shareholders Selling

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
2020	$4.90	30 June

AVR Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.